ROHTO's New Entry to Medical Aesthetics in EMEA region:
Strategic Business Partnership between ROHTO MediLuxe Europe and EMA AESTHETICS
Feb 1, 2024
ROHTO Pharmaceutical Co., Ltd. (Osaka, Japan; President: Masashi Sugimoto)
and ROHTO MediLuxe Europe S.A.S.U. (Paris, France; CEO: Nobuhiro Hirasawa),
a subsidiary of ROHTO Pharmaceutical hereafter referred to as ROHTO MLE,
are pleased to announce a strategic capital and business partnership with
EMA AESTHETICS Limited(Dublin, Ireland; CEO: Malcolm Wall Morris), hereafter
referred to as EMA.
Background and Objectives of the Strategic Alliance:
In recent years, the global medical aesthetic market has garnered attention
for its high efficacy and benefits, surpassing the pace of the mass skincare
market. The EMEA region (Europe, the Middle East, and Africa) has been
leading global trends in medical aesthetics, alongside North America, with
anticipated high growth and potential future impact on Asia and Japan.
EMA is expanding its business of non-invasive aesthetic treatment devices
globally, originally started from EMEA region, while the ROHTO Group possesses
foundational research and formulation development capabilities in healthcare
and skincare, actively conducting business in more than 110 countries around
the world, mainly in Japan and Asian markets.
This alliance is expected to provide an opportunity for the ROHTO Group
to expand its medical aesthetic business in the EMEA region and other areas,
taking the opportunity of an innovative approach leveraging the strengths
of both companies.
Nobuhiro Hirasawa, CEO of ROHTO MediLuxe Europe says;
This partnership is not only based on the synergy between innovative devices
and regenerative medical expertise along with unique skincare formulation
technology, but also on the synergy of EMA's ability to continuously create
new businesses and ROHTO's thorough customer-oriented approach. At the
milestone of our 125th anniversary, we are excited to enter the dynamic
field of aesthetic medicine, crossing borders from Paris, and look forward
to proposing new value to the world.
Malcolm Wall Morris, CEO of EMA AESTHETICS says;
Since its inception in 2019, EMA Aesthetics has consistently been a pioneer
in aesthetic products. Our philosophy of continual innovation, driven by
our dedication to surpass industry norms and exceed stakeholders' expectations,
has been pivotal in our journey. The partnership with ROHTO signifies a
key moment in our trajectory. Jointly, we are poised to push the limits
of aesthetic products, enhancing our worldwide presence and reiterating
our commitment to excellence and innovation.
Establishment of ROHTO MediLuxe Europe:
ROHTO Pharmaceutical established its subsidiary, ROHTO MediLuxe Europe,
in France on October 6, 2023. Using France as a base, the company plans
to explore new businesses and generate demand for next-generation products,
considering the deep historical and geographical ties with regions like
the Middle East and Africa.
Company Overview:
ROHTO MediLuxe Europe S.A.S.U.
CEO |
Nobuhiro Hirasawa |
Director |
Hidetoshi Segi |
Address |
22 Boulevard Malesherbes, 75008 Paris, France |
Establishment |
October 6, 2023 |
Business |
Investment and business operation in medical aesthetic and other health
and beauty field |
EMA AESTHETICS LIMITED
Founder |
Elias Chabtini, Malcolm Wall Morris |
CEO |
Malcolm Wall Morris |
Address |
Palmerston House Fenian Street Dublin 2, Ireland |
Establishment |
2019 |
Business |
Manufacture and sales of medical aesthetic devices and cosmetics and IoT
business |